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ABSTRACT
Introduction: Rapid identification of
bloodstream pathogens provides crucial
information that can improve the choice of
antimicrobial therapy for children. Previous
impact studies have primarily focused on
adults. Our objective was to evaluate the
impact of rapid testing in a children’s hospital
on time to organism identification and
antibiotic use in the setting of an established
antimicrobial stewardship program.
Methods: We conducted a retrospective study
over three consecutive time periods (spanning
January 2013–August 2015) as our hospital
sequentially introduced two rapid testing
methods for positive blood cultures. An
antimicrobial stewardship program was active
throughout the study. In the baseline period, no
rapid diagnostic methods were routinely
utilized. In the second period (PNAFISH), a
fluorescent in situ hybridization test was
implemented for gram-positive organisms and
in the third a rapid multiplex PCR (rmPCR) test
was employed. For children with positive blood
cultures, time to organism identification use
and duration of select antimicrobial therapies
were compared between periods.
Results: Positive blood cultures were analyzed.
Median overall time to organism identification
was 23, 11, and 0 h in the baseline, PNAFISH,
and rmPCR periods, respectively (p\0.001 for
both PNAFISH and rmPCR vs. baseline). For
gram-negative organisms, only rmPCR
performed significantly faster than baseline
(p\0.001). The duration of vancomycin use
for coagulase-negative staphylococci was
shorter in both the PNAFISH and rmPCR
periods (mean 31 h in the baseline period, 12
and 14 h in the PNAFISH and rmPCR periods,
respectively). For MSSA bacteremia, use of
vancomycin was significantly decreased only
in the rmPCR period (32% of patients vs. 64 and
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72% in the baseline and PNAFISH periods; mean
duration of 9 h vs. 30 and 26 h). There was no
difference in use or duration of broad-spectrum
gram-negative therapy across the three time
periods.
Conclusion: Rapid diagnostic testing for
children with positive blood cultures results in
faster time to identification and can influence
antibiotic prescribing in the setting of active
antimicrobial stewardship particularly for
gram-positive pathogens.
Funding: Merck.
Keywords: Antibiotic use; Antimicrobial
stewardship; Bloodstream infection; Molecular
testing; Rapid diagnostic methods
INTRODUCTION
Rapid testing for identification of pathogens in
bloodstream infections has the potential to
provide crucial information that can improve
patient care. There are a number of potential
benefits to rapid pathogen identification,
including decreased mortality from sepsis,
more targeted diagnostic and therapeutic
interventions, and more rapid optimization of
antimicrobial therapy.
The Infectious Diseases Society of America has
called for research on the impact of rapid
diagnostic testing on the use of antimicrobials
[1]. Studies in adults evaluating the clinical impact
of rapidbloodculturediagnosticsonantimicrobial
use have shown decreases in both the time to
effective or optimal therapy and the reduction in
the use of broad-spectrum agents [2–8]. Decreased
use of broad-spectrum therapy for patients who
can be treatedwith amore narrow-spectrumagent
could reduce the incidence of adverse outcomes
such asClostridiumdifficile colitis or the emergence
of resistant pathogens [9–11]. Studies evaluating
the impact of rapid diagnostic methods for blood
cultures in children are more limited. Initial
studies focused primarily on the diagnostic
accuracy and functionality of the tests [12–16];
however,more recent reports have shownbenefits
of rapid identification on overall antibiotic use in
children [2, 17–22].
In adult studies, antimicrobial stewardship
program (ASP) activities have proved to be a key
component in effectively translating rapid
diagnostics results into changes in patient care.
Prior pediatrics studies evaluating the impact of
rapid blood culture diagnostics have had either
limited formal ASP involvement [20, 21] or
implemented stewardship simultaneously with
the rapid diagnostic test [22]. Our institution has
had an active ASP since 2010. Our ASP provides
prospective audit and feedback guidance to
providers regarding antimicrobial therapy. Three
years after our ASP was started our institution
sequentially implemented two rapid diagnostic
platforms for pathogen identification in positive
blood cultures over 2 years (2013–2015). First, a
fluorescent in situ hybridization (PNA FISH) test
targeting gram-positive organism was
implemented, followed by a rapid multiplex PCR
(rmPCR) with an expanded panel targeting both
gram-positive and -negative pathogens that
replaced most use of the PNA FISH. Our
objective in this study was to evaluate the
impact of these tests on time to organism
identification in our hospital and to examine the
impact of rapid testing on antibiotic use for
specific pathogens in the setting of an
established ASP.
METHODS
Statement of Ethics Compliance
Approval for this study was obtained from the
Institutional Review Board of the University of
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Utah and Primary Children’s Hospital (PCH)
with a waiver of informed consent. All
procedures followed were in accordance with
the ethical standards of the responsible
committee on human experimentation
(institutional and national) and with the
Helsinki Declaration of 1964, as revised in 2013.
Setting
PCH is a 289-bed children’s hospital that is part
of Intermountain Healthcare. PCH serves as
both the pediatric community hospital for Salt
Lake County, Utah, and as the tertiary pediatric
referral center for five states in the
Intermountain West (Utah, Idaho, Wyoming,
Nevada, and Montana).
Study Design and Population
This was a retrospective study of positive blood
cultures from hospitalized patients evaluated at
PCH between 1 January 2013 and 15 August
2015. Positive blood cultures were identified
from the Intermountain Healthcare Enterprise
Data Warehouse (EDW); only the first positive
blood culture from an episode of bacteremia
was included in the study. Episodes of
bacteremia started with the first day of
positive blood cultures in a patient with no
known positive blood cultures in the previous
7 days. If children had multiple episodes of
bacteremia, each episode was included in the
analysis. Polymicrobial bacteremias were
excluded from analysis. Data abstracted from
the EDW included demographics, site of care,
timing of blood culture results reporting, time
to organism identification, antimicrobial
therapy given, and duration.
Study Timeline and Methods to Identify
Organisms in Positive Blood Cultures
The study was divided into three distinct
periods of 1–1.5 years based on the type of
diagnostic method used. Periods were defined
as: baseline (1 January–31 December 2013),
PNAFISH (1 January 2013–31 January 2014),
and rmPCR (1 February 2014–15 August
2015). Throughout the study, blood cultures
were processed in the clinical microbiology
laboratory using the BACTEC automated
blood culture system (BD Diagnostic Systems,
Franklin Lakes, NJ). Gram stains and rapid
diagnostic tests (when available and
indicated) were performed 24 h a day, 7 days
a week, by trained microbiology staff. Post
gram stain, organisms were inoculated onto
culture media and subsequently identified
using the VITEK 2 system (bioMe´rieux,
Marcy L’E´toile, France) and other
biochemical tests as appropriate.
Baseline Study Period (1 January–31
December 2013)
During the baseline period, no rapid diagnostic
methods were used for positive blood cultures.
Gram stain was performed immediately when a
blood culture signaled positive, and results were
exported into the electronic information
system. In addition, the positive blood culture
gram stain result was called to the treating
physician within 1 h of the positive BACTEC
alert. After biochemical identification,
Staphylococcus aureus was sub-cultured onto
solid media and early growth tested for the
presence of PBP2a using the PBP2a SA Culture
Colony Test (AlereTM, Waltham, MA).
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PNAFISH Study Period (1 January 2013–31
January 2014)
Peptide nucleic acid (PNA) fluorescent in situ
hybridization (QuickFISH, AvanDx, Inc.,
Woburn,MA) was implemented in the PCH
microbiology laboratory in January, 2013.
QuickFISH was performed for gram stains
showing gram-positive cocci in clusters
(Staphylococcus QuickFISHTM) starting in
January 2013 and was expanded to
gram-positive cocci in chains (Enterococcus
QuickFISHTM) in May 2013. Staphylococcus
QuickFISH identifies Staphylococcus aureus and
coagulase-negative staphylococci (CONS), and
Enterococcus QuickFISH identifies Enterococcus
faecalis and non-faecalis enterococci in about
20 min. PNA-FISH assays for gram-negative
organisms and Candida spp., while available
commercially, were not used in the PCH
laboratory. Microbiology staff reported
QuickFISH results for gram-positive organisms
when available as the first notification of a
positive blood culture. If QuickFISH was not
indicated (i.e., for gram-negative organisms) or
results were not available within an hour, the
treating physician was notified of the gram stain
result only. Further organism identification was
the same as in the baseline period, including
sub-culture of S. aureus after identification for
the detection of PBP2a using the PBP2a SA
Culture Colony Test.
rmPCR Study Period (1 February 2014–15
August 2015)
A multiplex PCR test [FilmArray blood culture
ID panel (BCID), BioFire Diagnostics LLC., Salt
Lake City, UT] was implemented in the PCH
microbiology laboratory in February 2014. This
assay detects 24 pathogens and 3 antibiotic
resistance genes, including Staphylococcus
aureus, Streptococcus pneumoniae, Enterococcus
species, Escherichia coli, Klebsiella species,
Enterobacter cloacae complex as well as mecA
(methicillin resistance), vanA/B (vancomycin
resistance), and KPC (carbapenem resistance)
in about 1 h [23]. BCID was performed on the
first positive aerobic blood culture and replaced
most, but not all, use of QuickFISH. QuickFISH
was still performed for gram-positive organisms
in anaerobic blood cultures and to distinguish
E. faecalis from other enterococci. Microbiology
staff called rapid diagnostic test results (BCID or
QuickFISH) to the treating physician as the first
report of a positive culture; if rapid diagnostic
results were not available within an hour of
positive BACTEC notification, the gram stain
alone was reported. Further organism
identification proceeded as before, although
PBP2a testing was not used routinely for S.
aureus, as mecA testing is part of the BCID test
panel.
Time to Organism Identification
First clinician notification of a positive blood
culture result, whether gram stain, QuickFISH,
or BCID result, was considered ‘‘Time 0’’ for all
analyses in this study. Organism identification
was defined as the first identification of an
organism to a group or genus (e.g.,
Enterobacteriaceae, Enterococcus spp.) or
species level identification (Fig. 1). Time to
organism identification was calculated as the
difference in time in hours between the first
clinician notification (Time 0) and the
identification of the organism.
Antimicrobial Stewardship Program (ASP)
and Interventions
Formal antimicrobial stewardship was
implemented at PCH in 2010. The PCH ASP
558 Infect Dis Ther (2016) 5:555–570
team consists of one pediatric infectious
diseases physician and a dedicated pharmacist.
The PCH ASP utilizes a prospective audit and
feedback model to provide antimicrobial use
recommendations to clinicians. All inpatients
receiving intravenous antimicrobials are
reviewed by the ASP Monday through Friday,
and physicians are contacted by the ASP
between 0700 and 1530 regarding
recommended changes to antimicrobial
Fig. 1 Blood culture procedures and methods to identify
pathogens from positive cultures in each time period are
shown. ‘‘Time 0’’ is deﬁned here as the ﬁrst call to the
clinician after the blood culture becomes positive.
Table shows examples of ‘‘ﬁrst clinician calls’’ for select
organisms
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therapy. Throughout the study, selected
antimicrobials (e.g., carbapenems, linezolid)
required ASP approval between 0700 and 2200
and, if given outside of these hours, was
reviewed by 1200 the next day. Vancomycin
use was not restricted, but was reviewed.
Upon updating any positive sterile site
culture, the PCH electronic health system
generates a notification of updated results
including gram stain, organism identification
(if available), and susceptibility results (if
available) to the ASP Pharmacist pager. For the
entirety of the study period, the PCH ASP
reviewed automated pages in real-time Monday
through Friday from 0700 to 1530 and used this
information to provide therapeutic
recommendations to the treating physicians.
Prior to implementation of the BCID panel, a
handout describing the interpretation of results
and suggestions for preferred antibiotic regimens
was distributed to physicians and pharmacists
throughout the hospital.
Antibiotic Use
Select antimicrobial therapy, specifically the use
of broad-spectrum gram-negative agents
(carbapenems, cefepime, ceftazidime, and
piperacillin-tazobactam) and vancomycin, was
evaluated (see below).
Vancomycin
For vancomycin, we examined overall use
measured as the percentage of all patients that
received at least one dose, as well as use of
vancomycin specifically for children with blood
cultures positive for MSSA and
coagulase-negative staphylococci (CoNS). For
vancomycin analyses in children with CoNS
bacteremia, we excluded children with multiple
positive blood cultures, infants hospitalized in
the neonatal ICU, and those with central lines
in order to identify a population where the
positive blood culture was likely to represent
contamination.
Broad-Spectrum Gram-Negative Agents
For broad-spectrum gram-negative agents, we
examined overall use as well as use specifically
for children with blood cultures positive for
gram-negative pathogens.
Outcome Measures and Statistical
Analyses
The primary outcome measures were the time
to organism identification and the use of select
antimicrobial therapy as described above.
Descriptive statistics were used to characterize
the pattern of microbiological detections and
the frequency and duration of antimicrobial
use. The median time to organism
identification was calculated. This value is
presented because for a minority of organisms
time to identification is very long, resulting in a
right bias. Antibiotic utilization is presented as
mean hours, which is a more clinically
meaningful metric. Additionally, because for
many patients utilization is 0 h, leading to a
large left bias in duration of use, we also present
the percent of patients receiving at least one
dose of each antibiotic. Categorical
comparisons were performed using the
chi-squared test or Fisher’s exact test, as
appropriate. Continuous comparisons were
performed using the Wilcoxon-Mann-Whitney
U test. All statistical tests were performed
two-sided with alpha equal to 0.05 using R (R
Foundation for Statistical Computing, Vienna,
Austria).
560 Infect Dis Ther (2016) 5:555–570
RESULTS
Study Cohort
A total of 1419 bacteremic episodes were
identified during the 3-year study period. Of
these, 191 (13%) were polymicrobial and were
excluded from analysis, leaving 1228
bacteremic episodes included in the study. The
number of episodes analyzed in each time
period was similar (397, 408, and 422 in the
baseline, PNAFISH, and rmPCR periods,
respectively). Demographic characteristics and
site of treatment for included children were also
similar and are shown in Table 1. We found no
significant differences between periods in
length of stay (8, 7, and 9 days), 30-day
mortality (4.3%, 4.2%, 3.5%), and 30-day
representation to the emergency department
or inpatient admission (39%, 40%, 44%) for the
baseline, PNAFISH, and rmPCR periods,
respectively.
Microbiology
Of 1228 first-positive blood cultures, 923 (75%)
were positive for gram-positive organisms, 280
(23%) were positive for gram-negative
organisms, and 22 (2%) were positive for
Candida species. The distribution of organisms
was comparable in the three periods.
Specifically, the number of gram-negative
Table 1 Demographics and treatment site for included children
Demographics N (%) or median (IQR)
Period
Overall (N5 1228) Baseline (N5 397) PNAFish (n5 408) rmPCR (N5 422)
Male 709 (58%) 213 (54%) 242 (59%) 253 (60%)
Age, years 2 (0–8) 2 (0–7) 2 (0–8) 2 (0–7)
Central line in place 447 (36%) 161 (41%) 149 (37%) 137 (32%)
Patient location at time 0
Admitted 984 (80%) 308 (78%) 330 (81%) 345 (82%)
General wards 422 (34%) 130 (33%) 141 (35%) 150 (36%)
ICU (PICU/CICU)a 246 (20%) 75 (19%) 83 (20%) 88 (21%)
NICUb 131 (12%) 42 (11%) 44 (11%) 45 (11%)
ICSc 176 (14%) 57 (14%) 60 (15%) 59 (14%)
Other 9 (1%) 4 (1%) 2 (0%) 3 (1%)
Not admitted 244 (20%) 89 (22%) 78 (19%) 77 (18%)
No active encounter 216 (18%) 78 (20%) 68 (17%) 70 (17%)
ED/RTUd 28 (2%) 11 (3%) 10 (2%) 7 (2%)
a ICU intensive care unit; PICU pediatric ICU; CICU cardiac ICU
b NICU neonatal ICU
c Immune compromised unit: unit for patients with malignancy, organ transplantation or other immune compromising
condition
d RTU rapid treatment (short stay) unit
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pathogens as well as staphylococci, including
CONS and MSSA, were not significantly
different between time periods. In the
PNAFISH period, 54% of organisms were
identified by the rapid diagnostic test
(QuickFISH), and in the rmPCR period, rapid
testing (BCID or QuickFISH) identified 89% of
organisms. Data are shown in Table 2.
Time to Organism Identification
In the baseline period, the median time to
organism identification from time 0 across all
organisms was 23 h (IQR 16–31 h; Table 2).
Median time to identification for
gram-positive organisms was 21 h (IQR
15–28 h) as well as median time to
identification for gram-negatives was 34 h
(IQR 26–43 h). Time to identification for all
organisms was shorter in both the PNAFISH
(median 11 h; IQR 0–29) and the rmPCR periods
(median 0 h; IQR 0–2). For gram-negative
organisms and Candida species, time to
identification was shorter only in the rmPCR
period (median 1 h; IQR 0–5) as these organisms
were not included in the PNAFISH rapid testing
algorithm. However, the median time to
identification was shorter for gram-positive
organisms (mean of 0 h) in both the PNAFISH
(IQR 0–18 h) and rmPCR periods (IQR 0-1 h).
Antibiotic Utilization
Vancomycin
Overall, there was a trend toward decreased use
of vancomycin for children with positive blood
cultures when comparing the baseline period to
the periods in which rapid diagnostics were
used (Table 3). In both the PNAFISH and rmPCR
periods, there was a decrease in the percentage
of children with CoNS bacteremia who received
any vancomycin as well as a significant trend
toward shorter duration of vancomycin
therapy. While there was no significant
difference in the use of vancomycin for
children with MSSA bacteremia in the
PNAFISH period when compared to baseline
(64% and 72% of children treated with
vancomycin, respectively), the percentage of
children with blood cultures positive for MSSA
who received any doses of vancomycin declined
considerably during the rmPCR period (32%;
p = 0.01 for rmPCR compared to baseline). This
was also reflected in an overall decreased
duration of vancomycin use for children with
MSSA bacteremia (mean duration of 9 vs. 30 h
in the baseline period).
Broad-Spectrum Gram-Negative Antibiotics
In contrast to vancomycin, we found no
difference between periods in the use of
broad-spectrum gram-negative agents,
including carbapenems. Overall, 22% of
children with a positive blood culture received
broad-spectrum gram-negative agents and 37%
because their blood culture was positive for a
gram-negative pathogen. Duration of therapy
was also not statistically different between
periods. Overall mean duration of
broad-spectrum gram-negative therapy was 28,
47 h if a gram-negative pathogen was identified.
Results are shown in Table 3.
DISCUSSION
We evaluated the impact of two different rapid
molecular diagnostics on the time to
identification of organisms as well as select
antibiotic prescribing for bloodstream
pathogens in a children’s hospital with a
mature ASP. We found that the use of both
PNA FISH and rmPCR significantly decreased
the median time to identification of
gram-positive organisms, and rmPCR also
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Table 3 Antibiotic utilization in the baseline, PNAFish, and rmPCR periods
Denominatora Antibiotic
used?
Duration of use p valuec
Yes ‡24 hb Mean
(–SD)
duration, h
Vancomycin 1228 566 (46%) 452 (37%) 44 (±98) –
Baseline 397 197 (50%) 161 (41%) 53 (±119) Ref.
PNAFish 408 196 (48%) 164 (40%) 44 (±94) 0.20
rmPCR 422 172 (41%) 126 (30%) 35 (±79) 0.01
Vancomycin ? CoNSd 248 66 (27%) 54 (22%) 19 (±57) –
Baseline 82 27 (33%) 25 (30%) 31 (±81) Ref.
PNAFish 74 17 (23%) 14 (19%) 12 (±29) 0.05
rmPCR 91 21 (23%) 14 (15%) 14 (±45) 0.10
Vancomycin ?MSSA 124 69 (56%) 49 (40%) 22 (±33) –
Baseline 44 28 (64%) 21 (48%) 30 (±45) Ref.
PNAFish 39 28 (72%) 22 (56%) 26 (±23) 0.55
rmPCR 41 13 (32%) 6 (15%) 9 (±19) 0.01
Broad-spectrum gram-negative antibioticse 1228 265 (22%) 212 (17%) 28 (±105) –
Baseline 397 68 (17%) 59 (15%) 26 (±108) Ref.
PNAFish 408 88 (22%) 72 (18%) 27 (±94) 0.91
rmPCR 422 108 (26%) 80 (19%) 31 (±111) 0.56
Broad-spectrum gram-negative
antibiotics ? gram-negative organismse
280 104 (37%) 87 (31%) 47 (±118) –
Baseline 90 31 (34%) 29 (32%) 53 (±143) Ref.
PNAFish 84 24 (29%) 21 (25%) 37 (±102) 0.40
rmPCR 106 49 (46%) 37 (35%) 51 (±105) 0.88
Carbapenems 1228 130 (11%) 118 (10%) 20 (±100) –
Baseline 397 44 (11%) 43 (11%) 20 (±95) Ref.
PNAFish 408 38 (9%) 33 (8%) 20 (±97) 0.99
rmPCR 422 47 (11%) 41 (10%) 20 (±107) 0.98
Carbapenems ? gram-negative organisms 280 70 (25%) 64 (23%) 40 (±123) –
Baseline 90 29 (32%) 29 (32%) 55 (±144) Ref.
PNAFish 84 12 (14%) 10 (12%) 29 (±117) 0.19
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decreased the time to identification for
gram-negative organisms. Rapid identification
of CoNS in both the PNAFISH and rmPCR
periods was associated with decreased use of
vancomycin, but only rmPCR was associated
with a significant decrease in vancomycin
exposure for children with MSSA. In contrast,
we did not observe changes in the use of
broad-spectrum gram-negative antibiotics
associated with the use of either diagnostic test.
Prior studies have shown decreased time to
identification of organisms using rapid
diagnostic methods, such as QuickFISH,
FilmArray BCID, and Verigene compared to
standard culture-based methods
[18, 20, 24–27]. While this is not unexpected,
direct comparative studies between methods
have not been performed in pediatrics. As the
majority of rapid diagnostic tests for positive
blood cultures identify only a limited set of
pre-defined pathogens, the overall impact of
each test may vary depending on differences in
the epidemiology of bloodstream pathogens. In
our population we found that both PNA FISH
and rmPCR provided identification for
gram-positive pathogens a full day sooner
than standard techniques. Using a combined
panel identifying both gram-positive and
-negative organisms, rmPCR characterized 89%
of all positive blood culture organisms within
an hour. QuickFISH is available for
gram-negative organisms as well but was not
implemented at our institution.
Recent studies in adults have demonstrated
that rapid identification of bloodstream
pathogens can decrease the use of vancomycin
[2, 6, 7, 28]. This finding was replicated for
children in our study. Relative to a period with
no rapid testing, we found that both PNA FISH
and rmPCR decreased the duration of
vancomycin therapy for all children with
positive blood cultures. There were, however,
specific differences in the effect of testing on
different pathogens, for example, CoNS and
MSSA. CoNS is a pathogen for which
identification alone predicts care. When
considered pathogenic, CoNS is almost
exclusively treated with vancomycin; however,
in many cases it is simply a blood culture
contaminant, requiring no antibiotic therapy.
As identification of CoNS (or, more specifically,




Duration of use p valuec
Yes ‡24 hb Mean
(–SD)
duration, h
rmPCR 106 29 (27%) 25 (24%) 37 (±107) 0.32
a Denominator is the number of bacteremic episodes in each category. For example, the total number of bacteremic episodes
in the baseline period is 397; the total number of bacteremic episodes in which CoNS was identiﬁed is 82 in the baseline
period
b Total number (percent) of episodes in which the antibiotic was used for[24 h. The denominator is the total number of
episodes in the category
c All p values are reported in comparison to the duration in the baseline period
d CoNS infections were included for children in whom CoNS was isolated from a blood culture that was not drawn from a
central line and not drawn in the newborn intensive care unit
e Broad-spectrum gram-negative antibiotics include carbapenems, piperacillin/tazobactam, and cefepime
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therapy decisions, we observed a decrease in
vancomycin therapy in both the PNAFISH and
rmPCR periods for children in whom CoNS was
likely a contaminant organism (excluding
children with multiple positive blood cultures,
infants hospitalized in the neonatal ICU, and
those with central lines; see ‘‘Methods’’).
In contrast, optimizing care for children with
S. aureus bacteremia requires identification of
both the pathogen and a resistance marker.
Thus, we observed a significant reduction in
duration of vancomycin use for MSSA
bacteremia during the rmPCR but not the
PNAFISH period. In both adult and pediatric
studies, treatment of MSSA bacteremia with
nafcillin or cefazolin decreases mortality when
compared to treatment with vancomycin
[29–32]. The reduction in vancomycin use
observed in our study is likely related to the
fact that the rmPCR used both identified S.
aureus and evaluates for the presence or absence
of mecA simultaneously, whereas PNAFISH
identified only the pathogen. Nguyen et al.
showed a decrease in the duration of
vancomycin use when using PCR to detect the
mecA gene in positive blood cultures [6]. Beal
et al., using a multiplex DNA hybridization
assay, found that the rapid detection of MSSA
(vs. MRSA) allowed for a reduction in time to
optimal antibiotics of 21 h for adult patients
[33]. Our findings for both CoNS and MSSA are
similar to those of Pardo et al. who looked at the
impact of the BCID panel on the management
of patients with blood cultures positive for
gram-positive organisms [34].
We did not find a reduction in the use of
broad-spectrum gram-negative agents with the
introduction of either PNAFISH or rmPCR.
Explanations of these findings include our
low, but non-trivial institutional rate of
gram-negative resistance for pathogens in
bacteremia (10% ceftriaxone resistance among
gram-negative pathogens) as well as ASP
activities resulting in well-controlled use of
broad-spectrum agents prior to the start of this
study. In a previous study, Buss et al. failed to
improve outcomes in high-risk children with
gram-negative bacteremia utilizing MALDI-TOF
combined with a robust ASP in a large tertiary
care hospital with low institutional resistance
rates similar to ours [35]. Additionally, while
the rmPCR test used in our study reported
resistance to carbapenems mediated by the KPC
gene, it did not provide information regarding
susceptibility or resistance to third-generation
cephalosporins. Without data on resistance, the
ability and desire of clinicians to rapidly
de-escalate therapy for bloodstream infection
is limited. Finally, many gram-negative
bloodstream infections are part of a
polymicrobial or complex process such as an
intra-abdominal infection, necessitating
broad-spectrum therapy even when the
identified pathogen could be more narrowly
treated. However, with low resistance rates
among gram-negative organisms in children’s
hospitals in general [36, 37] as well as lower
mortality from sepsis [38, 39], the opportunity
for early de-escalation and reduction in
selection pressure is great. Expansion of rapid
testing to include gram-negative resistance
markers is critical.
This study has several limitations. First, it was
performed at a single freestanding children’s
hospital and our results may not be generalizable
to other settings with different bacterial
epidemiology and resistance patterns. Second,
this was a retrospective study comparing trends
over time and did not use randomization or
concurrent controls. Finally, our focus was on
utilization of select agents overall and in specific
clinical circumstances; we did not examine time
to effective or optimal therapy for patients
individually. It is possible that we may have
566 Infect Dis Ther (2016) 5:555–570
under-estimated the beneficial impact of rapid
diagnostics for positive blood cultures as a result.
There are other potential benefits to more rapid
identification of bloodstream pathogens that
remain unmeasured in our study as well as
others. These include the ability to more
rapidly direct other aspects of care, including
diagnostic evaluation and source control. Future
studies should attempt to incorporate endpoints
that relate to these aspects of clinical care to
more fully understand the impact of rapid
testing. In addition, formal economic analysis
should be performed to determine the economic
value and cost-effectiveness of using these
platforms. Despite these limitations, this is the
largest study to our knowledge to evaluate the
impact of rapid diagnostic testing on antibiotic
prescribing for children with positive blood
cultures and the first to our knowledge to
evaluate two different rapid molecular methods
with conventional culture-based methods over
consecutive periods in the context of a mature
ASP.
CONCLUSIONS
In conclusion, the introduction of rapid
diagnostic testing for children with positive
blood cultures results in faster time to organism
identification. More importantly, such tests can
be effective in decreasing unnecessary
antimicrobial use and can influence
prescribing of certain antibiotics for select
organisms, particularly vancomycin use for
MSSA and CoNS in certain clinical settings.
Further expansion of these panels to include
more comprehensive detection of
gram-negative resistance mechanisms is critical
to further improvements in antimicrobial use.
Implementation of rapid diagnostic tests can
have a powerful positive impact on care, even in
the setting of a mature ASP, and the benefits are
likely augmented by such a program.
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